by Peter Ciszewski | Jun 4, 2020
Ross Camidge, MD, PhD of the University of Colorado Cancer Center explains the Phase 3 ALTA 1L trial, which led to the approval of brigatinib as a first-line therapy to treat anaplastic lymphoma kinase-positive (ALK+) metastatic nnon-small cell lung cancer...
by Peter Ciszewski | Jun 3, 2020
Jorge Cortes, MD from the Georgia Cancer Center at Augusta University discusses interim data presented at the ASCO 2020 conference. The data comes from the open label phase II OPTIC study testing different dosages of ponatinib to treat chronic phase chronic...
by Peter Ciszewski | Jun 2, 2020
Ronald Hoffman, MD, Director of the Myeloproliferative Diseases Program at The Icahn School of Medicine at Mount Sinai, describes the complexities in diagnosing polycythemia vera. Polycythemia vera is a rare blood disorder characterized by increased...
by Peter Ciszewski | Jun 1, 2020
Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center provides an overview to acute myeloid leukemia (AML) and how new targeted treatments have completely transformed how AML patients are managed. AML is a rare bone marrow...
by Peter Ciszewski | May 29, 2020
Gary Grohmann, PhD, Director of the Australian Immunisation Coalition, discusses his concern that many people with medical conditions, including those with rare diseases, are not going to get the regular care then need to manage their chronic condition. Dr....
